Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: VISEN Pharmaceuticals

Market Cap 1.89B 2.19B 279M 243M 226M 211M 396M 26.35B 398M 2.68B 1.04B 12.97B 1.05B 1.03B 45.04B P/E 2026 *
-18.4x
P/E 2027 * -31x
Enterprise Value 1.63B 1.88B 241M 210M 194M 182M 341M 22.69B 343M 2.3B 893M 11.17B 903M 883M 38.79B EV / Sales 2026 *
24x
EV / Sales 2027 * 4.23x
Free-Float
19.1%
Yield 2026 *
-
Yield 2027 * -
1 day+2.19%
1 week+0.20%
Current month-12.38%
1 month-19.02%
3 months-22.75%
6 months-43.38%
Current year-38.72%
1 week 19.03
Extreme 19.03
20.16
1 month 19.03
Extreme 19.03
24
Current year 19.03
Extreme 19.03
43.3
1 year 19.03
Extreme 19.03
52.9
3 years 19.03
Extreme 19.03
69.15
5 years 19.03
Extreme 19.03
69.15
10 years 19.03
Extreme 19.03
69.15
Manager TitleAgeSince
Chief Executive Officer 60 2018-11-06
Director of Finance/CFO 42 2025-10-12
Chief Tech/Sci/R&D Officer 54 2020-03-31
Director TitleAgeSince
Director/Board Member 60 2018-11-06
Director/Board Member 44 2021-01-07
Director/Board Member 60 2021-03-31
Date Insider Type Main position Quantity % Market Cap.
12-31Other

Chief Executive Officer

108,750 0.0955%
Change 5-day change 1-year change 3-year change Capi.($)
+2.19%+0.20%-58.73% - 280M
+1.44%+1.71%-10.98%-6.19% 43.13B
+3.31%+5.93%+310.97%+534.70% 34.65B
+2.84%+2.14%+9.34%+41.02% 30.03B
-1.70%-7.54%+8.43%-21.94% 28B
-1.90%-1.56%+10.24%+21.21% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+104.27% 13.14B
-0.57%-2.43%+5.08%+4.79% 12.53B
-0.26%+1.15%+98.13%+80.47% 12.25B
Average +0.59%+0.52%+46.80%+94.79% 21.28B
Weighted average by Cap. +0.78%+1.27%+65.29%+110.06%

Financials

2026 *2027 *
Net sales 67.73M 78.42M 10.01M 8.73M 8.08M 7.56M 14.19M 944M 14.27M 95.86M 37.15M 465M 37.56M 36.76M 1.61B 447M 518M 66.1M 57.63M 53.38M 49.97M 93.71M 6.24B 94.28M 633M 245M 3.07B 248M 243M 10.66B
Net income -99M -115M -14.63M -12.75M -11.81M -11.06M -20.74M -1.38B -20.86M -140M -54.3M -679M -54.9M -53.72M -2.36B -58M -67.15M -8.57M -7.47M -6.92M -6.48M -12.15M -809M -12.22M -82.09M -31.81M -398M -32.16M -31.48M -1.38B
Net Debt -262M -304M -38.75M -33.79M -31.29M -29.3M -54.94M -3.66B -55.27M -371M -144M -1.8B -145M -142M -6.25B 486K 563K 71.81K 62.61K 57.99K 54.29K 102K 6.78M 102K 688K 267K 3.34M 270K 264K 11.58M
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
82
Date Price Change Volume
26-06-18 20.10 $ +2.19% 29,600
26-06-17 19.67 $ +1.24% 10,800
26-06-16 19.43 $ -1.92% 15,700
26-06-15 19.81 $ -1.25% 42,700
26-06-12 20.06 $ -1.57% 12,200
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.34CNY
Average target price
44.50CNY
Spread / Average Target
+156.66%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2561 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!